4D pharma plc announced the publication in the journal Alimentary Pharmacology & Therapeutics of the Phase II clinical data for LBP Blautix (MRx1234) for the treatment of irritable bowel syndrome. The results highlight the positive effects of Blautix on key regulator-defined clinical symptoms of IBS, altered bowel habits and abdominal pain, both in patients with IBS with predominant constipation (IBS-C) or IBS with predominant diarrhoea (IBS-D). Blautix was well tolerated, with a safety profile comparable to placebo.
1st Jan change | Capi. | |
---|---|---|
+16.44% | 122B | |
+18.94% | 113B | |
+18.75% | 26.22B | |
-25.37% | 19.01B | |
-19.63% | 15.71B | |
-20.20% | 15.22B | |
-47.37% | 14.72B | |
+59.91% | 14.58B | |
+4.35% | 13.84B |